C
C. Goessl
Researcher at AstraZeneca
Publications - 32
Citations - 4153
C. Goessl is an academic researcher from AstraZeneca. The author has contributed to research in topics: Olaparib & Prostate cancer. The author has an hindex of 12, co-authored 32 publications receiving 2384 citations.
Papers
More filters
Journal ArticleDOI
Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation
Mark E. Robson,Seock-Ah Im,Elżbieta Senkus,Binghe Xu,Susan M. Domchek,Norikazu Masuda,Suzette Delaloge,Wei Li,Nadine Tung,Anne Armstrong,Wenting Wu,C. Goessl,Sarah Runswick,Pierfranco Conte +13 more
TL;DR: Among patients with HER2‐negative metastatic breast cancer and a germline BRCA mutation, Olaparib monotherapy provided a significant benefit over standard therapy; median progression‐free survival was 2.8 months longer and the risk of disease progression or death was 42% lower with olaparIB monotherapy than with standard therapy.
Journal ArticleDOI
Olaparib for metastatic castration-resistant prostate cancer
Johann S. de Bono,Joaquin Mateo,Karim Fizazi,Fred Saad,Neal D. Shore,Shahneen Sandhu,Kim N. Chi,Oliver Sartor,Neeraj Agarwal,David Olmos,Antoine Thiery-Vuillemin,Przemyslaw Twardowski,Niven Mehra,C. Goessl,Jinyu Kang,J. Burgents,W. Wu,Alexander Kohlmann,Carrie A. Adelman,Maha Hussain +19 more
TL;DR: In men with metastatic castration-resistant prostate cancer who had disease progression while receiving enzalutamide or abiraterone and who had alterations in genes with a role in homologous recombination repair, olaparib was associated with longer progression-free survival and better measures of response and patient-reported end points than either enzalUTamide or monotherapy.
Journal ArticleDOI
OlympiAD final overall survival and tolerability results: Olaparib versus chemotherapy treatment of physician’s choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer
Mark E. Robson,Nadine Tung,Pierfranco Conte,S-A. Im,Elżbieta Senkus,Binghe Xu,Norikazu Masuda,Suzette Delaloge,Wei Li,Andrew J. Armstrong,W. Wu,C. Goessl,Sarah Runswick,Susan M. Domchek +13 more
TL;DR: There was the possibility of meaningful OS benefit among patients who had not received chemotherapy for metastatic disease, and olaparib was generally well-tolerated, with no evidence of cumulative toxicity during extended exposure.
Journal ArticleDOI
Olaparib combined with abiraterone in patients with metastatic castration-resistant prostate cancer: a randomised, double-blind, placebo-controlled, phase 2 trial.
Noel W. Clarke,Paweł Wiechno,Boris Alekseev,Nuria Sala,Robert H. Jones,Ivo Kocak,Vincenzo Emanuele Chiuri,Jacek Jassem,Aude Flechon,Charles H. Redfern,C. Goessl,Joseph Burgents,Robert Kozarski,Darren Hodgson,Maria Learoyd,Fred Saad +15 more
TL;DR: Olaparib in combination with abiraterone provided clinical efficacy benefit for patients with metastatic castration-resistant prostate cancer and preclinical data suggest synergy between olaparIB and androgen pathway inhibitors.
Journal ArticleDOI
PROfound: Phase III study of olaparib versus enzalutamide or abiraterone for metastatic castration-resistant prostate cancer (mCRPC) with homologous recombination repair (HRR) gene alterations
Maha Hussain,Joaquin Mateo,Karim Fizazi,Fred Saad,N. Shore,Shahneen Sandhu,Kim N. Chi,Oliver Sartor,Neeraj Agarwal,David Olmos,Antoine Thiery-Vuillemin,Przemyslaw Twardowski,Niven Mehra,C. Goessl,Jinyu Kang,J. Burgents,W. Wu,Alexander Kohlmann,Carrie A. Adelman,J.S. de Bono +19 more